VEGFR2/NFAT Reporter HEK293 Recombinant Cell Line
VEGFR2/NFAT Reporter HEK293 Recombinant Cell Line is a HEK293 cell line expressing the firefly luciferase reporter under the control of NFAT response elements. The cells also stably express human VEGFR2 (Human Vascular Endothelial Growth Factor Receptor 2; KDR, FLK1; ref seq. NM_002253.1).
Expression of VEGFR2 was assessed by flow cytometry and this cell line has been functionally validated with Sorafenib, Anti-VEGF Neutralizing Antibody and Aflibercept Biosimilar.
Interested in screening and profiling inhibitors, blocking antibodies, or activators of VEGFR2 without the need to purchase and license the cell line? Check out our Cell Signaling Pathway Screening.
This product has been cited 17 times.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
Media Required for Cell Culture
Name | Ordering Information |
Thaw Medium 1 | BPS Bioscience #60187 |
Growth Medium 1A | BPS Bioscience #79528 |
Materials Used in the Cellular Assays
Name | Ordering Information |
Human VEGF165 | BPS Bioscience #91001 |
Thaw Medium 1 | BPS Bioscience #60187 |
Protease-free Bovine Serum Albumin (BSA) | Sigma-Aldrich #A4919 |
Sorafenib | LC Laboratories #S-8599 |
Anti-VEGF Neutralizing Antibody | BPS Bioscience #79478 |
Aflibercept Biosimilar | Ichorbio #ICH4015 |
ONE-Step™ Luciferase Assay System | BPS Bioscience #60690 |
96-well tissue culture treated white clear-bottom assay plate | Corning #3610 |
Luminometer |
The cell line has been screened to confirm the absence of Mycoplasma species.
The interaction between VEGF (Vascular Endothelial Growth Factor) and its receptor VEGFR is an important mediator of angiogenesis as well as endothelial cell survival and proliferation. VEGFR2 is a receptor tyrosine kinase that plays a major role in cellular responses driven by VEGF. Targeting the kinase activity of VEGFR2 has been an attractive tool in cancer therapy based on its anti-angiogenesis effects. In addition to the kinase inhibitors, humanized monoclonal antibodies interfering with VEGF/VEGFR2 interaction have been also developed for anti-cancer treatments.